Q2 2025 Transmedics Group Inc Earnings Call Transcript

Jul 30, 2025 / 08:30 PM GMT

Release Date Price: €90.22 (-0.31%)

Transcript 10-Q8-K

Key Points

Positve

TransMedics Group Inc (TMDX) reported a 38% year-over-year revenue growth for Q2 2025, reaching $157.4 million.
The company achieved a new high water mark for clinical cases and revenue, demonstrating significant operating leverage.
TransMedics Group Inc (TMDX) maintained a steady gross margin of 61.4% in Q2 2025.
The company added approximately $90 million to its balance sheet, ending Q2 with over $400 million in cash.
TransMedics Group Inc (TMDX) received FDA conditional approval for the OCS lung IDE and is on track to launch both heart and lung clinical programs before year-end.

Negative

There is market confusion and noise following comments made by a competitor in the organ preservation ecosystem.
The company anticipates some minor and transient seasonality in Q3 performance due to summer vacation season.
Operating expenses increased by 6% year over year, driven by a 50% increase in R&D expenses.
The company faces potential challenges from the US National Transplant modernization initiative, which could impact smaller market players.
There is ongoing concern about the impact of oversight on DCD usage, which could affect the company's operations.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

TMDX.OQ - Transmedics Group Inc
Q2 2025 Transmedics Group Inc Earnings Call
Jul 30, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome to Transmedics 2nd quarter 2025 earnings conference call.

At this time, all participants are in listen-only mode. We will be facilitating a question and answer session towards the end of today's call.

As a reminder, this call is being recorded for replay purposes.

I would now like to turn the call over to Laine Morgan from the Gilmartin Group for a few introductory comments. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you. Earlier today, Transmetics released financial results for the quarter ended

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.